Atlas FDA

PATHWAY anti- HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody

FDA premarket approval P990081/S059 · decided 2025-12-15

Approval details

PMA number
P990081
Supplement
S059
Supplement type
Normal 180 Day Track
Supplement reason
Labeling Change - Indications/instructions/shelf life/tradename
Trade name
PATHWAY anti- HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody
Generic name
SYSTEM, TEST, HER-2/NEU, IHC
Applicant
Ventana Medical Systems, Inc.
Date received
2025-08-15
Decision date
2025-12-15
Days to decision
122 days
Decision code
APPR
Product code
MVC
Advisory committee
Pathology
Expedited review
No
Location
Tucson, AZ
Statement
This 180-day supplement is to expand labeling of the PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody assay for use as a companion diagnostic to identify patients with HER2-positive, advanced or metastatic breast cancer who may be eligible for treatment with ENHERTU (fam-trastuzumab deruxtecan-nxki) in combination with PERJETA (pertuzumab) as first-line treatment.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
Roche Digital Pathology Dx (K242783)Ventana Medical Systems, Inc.2024-12-17
VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail (08507023001) (DEN240025)Ventana Medical Systems, Inc.2024-12-05
Roche Digital Pathology Dx (VENTANA DP 200) (K232879)Ventana Medical Systems, Inc.2024-06-14
CINtec Histology (K212176)Ventana Medical Systems, Inc.2021-12-10
VENTANA CD30 (Ber-H2) RxDx Assay (K172471)Ventana Medical Systems, Inc.2018-05-08
CINtec Histology (50 tests), CINtec Histology (250 tests) (DEN160019)Ventana Medical Systems, Inc.2017-03-04
Virtuoso System for IHC PR (1E2) using iScan HT (K142965)Ventana Medical Systems, Inc.2015-07-16
VIRTUOSO SYSTEM FOR IHC ER (SP1) WITH BENCHMARK ULTRA STAINER (K140465)Ventana Medical Systems, Inc.2014-03-20